Total Payments
$1,321
2023 Payments
$114.35
Companies
9
Transactions
18
Medicare Patients
2,729
Medicare Billing
$244,913
Payment Breakdown by Category
Food & Beverage$1,321 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,321 | 18 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $360.06 | 4 | $0 (2023) |
| Alkermes, Inc. | $317.63 | 3 | $0 (2018) |
| Neurocrine Biosciences, Inc. | $282.15 | 2 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $130.46 | 2 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $120.00 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $48.81 | 1 | $0 (2017) |
| Novo Nordisk Inc | $35.27 | 3 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $14.97 | 1 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $11.53 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $114.35 | 1 | Otsuka America Pharmaceutical, Inc. ($114.35) |
| 2020 | $26.66 | 2 | AstraZeneca Pharmaceuticals LP ($14.97) |
| 2019 | $147.79 | 3 | Otsuka America Pharmaceutical, Inc. ($125.00) |
| 2018 | $652.42 | 6 | Neurocrine Biosciences, Inc. ($282.15) |
| 2017 | $379.66 | 6 | Alkermes, Inc. ($124.68) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/20/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $114.35 | General |
| Category: PSYCHIATRY | ||||||
| 02/25/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/12/2020 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Diabetes | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), ASMANEX, STEGLATRO | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/09/2019 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $11.26 | General |
| Category: Diabetes | ||||||
| 05/19/2019 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 11/06/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: CNS | ||||||
| 08/21/2018 | Alkermes, Inc. | Aristada 441 mg (Drug), Aristada 662mg, Aristada 882mg | Food and Beverage | In-kind items and services | $67.95 | General |
| Category: CNS | ||||||
| 05/24/2018 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $80.99 | General |
| Category: NEUROLOGY | ||||||
| 05/23/2018 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $57.32 | General |
| Category: Neuroscience | ||||||
| 05/07/2018 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $201.16 | General |
| Category: NEUROLOGY | ||||||
| 04/10/2018 | Alkermes, Inc. | Aristada 441 mg (Drug), Aristada 662mg, Aristada 882mg | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: CNS | ||||||
| 11/08/2017 | Alkermes, Inc. | Aristada 441 mg (Drug), Aristada 662mg, Aristada 882mg | Food and Beverage | In-kind items and services | $124.68 | General |
| Category: CNS | ||||||
| 11/02/2017 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $64.98 | General |
| Category: PSYCHIATRY | ||||||
| 10/26/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $55.73 | General |
| Category: PSYCHIATRY | ||||||
| 09/14/2017 | Janssen Pharmaceuticals, Inc | INVEGA TRINZA (Drug), INVEGA SUSTENNA | Food and Beverage | In-kind items and services | $73.14 | General |
| Category: Neuroscience | ||||||
| 04/27/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $48.81 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/06/2017 | Novo Nordisk Inc | Victoza (Drug), Tresiba | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 837 | 3,756 | $338,369 | $83,002 |
| 2022 | 26 | 689 | 2,965 | $230,537 | $60,598 |
| 2021 | 26 | 613 | 2,196 | $215,349 | $51,607 |
| 2020 | 26 | 590 | 13,707 | $215,548 | $49,705 |
Total Patients
2,729
Total Services
22,624
Medicare Billing
$244,913
Procedure Codes
109
All Medicare Procedures & Services
109 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 22 | 2,700 | $146,016 | $49,184 | 33.7% |
| 77067 | Screening mammography | Office | 2023 | 89 | 89 | $33,325 | $7,478 | 22.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 39 | 40 | $23,462 | $4,139 | 17.6% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 153 | 190 | $17,374 | $2,851 | 16.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 28 | 28 | $15,906 | $2,529 | 15.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 12 | 19 | $9,606 | $1,821 | 19.0% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 32 | 35 | $10,641 | $1,732 | 16.3% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Office | 2023 | 23 | 27 | $11,675 | $1,696 | 14.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 19 | 34 | $7,922 | $1,604 | 20.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 51 | 126 | $8,153 | $1,302 | 16.0% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 23 | 24 | $8,337 | $1,294 | 15.5% |
| 72114 | X-ray lower and sacral spine, minimum of 6 views | Office | 2023 | 29 | 29 | $5,418 | $897.26 | 16.6% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 14 | 14 | $4,244 | $638.52 | 15.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 30 | 40 | $2,617 | $586.16 | 22.4% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 12 | 22 | $4,020 | $528.00 | 13.1% |
| 76705 | Limited ultrasound scan of abdomen | Office | 2023 | 12 | 12 | $2,978 | $527.40 | 17.7% |
| 73030 | X-ray of shoulder, minimum of 2 views | Office | 2023 | 29 | 29 | $2,823 | $506.52 | 17.9% |
| 73564 | X-ray of knee, 4 or more views | Office | 2023 | 16 | 18 | $2,590 | $433.54 | 16.7% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 13 | 23 | $2,540 | $428.56 | 16.9% |
| 73502 | X-ray of hip, 2-3 views | Office | 2023 | 13 | 14 | $1,930 | $371.14 | 19.2% |
| 73610 | X-ray of ankle, minimum of 3 views | Office | 2023 | 16 | 18 | $2,006 | $334.88 | 16.7% |
| 73630 | X-ray of foot, minimum of 3 views | Office | 2023 | 16 | 18 | $1,871 | $327.08 | 17.5% |
| 74019 | X-ray of abdomen, 2 views | Office | 2023 | 16 | 18 | $1,801 | $322.83 | 17.9% |
| 72100 | X-ray of lower and sacral spine, 2-3 views | Office | 2023 | 17 | 17 | $1,930 | $299.88 | 15.5% |
| 73562 | X-ray of knee, 3 views | Office | 2023 | 12 | 14 | $1,716 | $277.44 | 16.2% |
About Dr. Sebastian Baginski, M.D
Dr. Sebastian Baginski, M.D is a Hospice and Palliative Medicine healthcare provider based in Pittsfield, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1891831566.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sebastian Baginski, M.D has received a total of $1,321 in payments from pharmaceutical and medical device companies, with $114.35 received in 2023. These payments were reported across 18 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($1,321).
As a Medicare-enrolled provider, Baginski has provided services to 2,729 Medicare beneficiaries, totaling 22,624 services with total Medicare billing of $244,913. Data is available for 4 years (2020–2023), covering 109 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospice and Palliative Medicine
- Other Specialties Family Medicine, Geriatric Medicine
- Location Pittsfield, IL
- Active Since 01/30/2007
- Last Updated 04/22/2014
- Taxonomy Code 207QH0002X
- Entity Type Individual
- NPI Number 1891831566
Products in Payments
- Aristada 441 mg (Drug) $317.63
- INGREZZA (Drug) $282.15
- REXULTI (Drug) $170.08
- LATUDA (Drug) $120.00
- INVEGA TRINZA (Drug) $73.14
- ABILIFY MAINTENA (Drug) $64.98
- INVEGA SUSTENNA (Drug) $57.32
- ENTRESTO (Drug) $48.81
- Ozempic (Drug) $22.95
- FARXIGA (Drug) $14.97
- Victoza (Drug) $12.32
- JANUVIA (Drug) $11.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.